|  | 
| CRLX101 plus olaparib in patients with metastatic castration-resistant prostate cancer. | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| Speakers' Bureau - Boehringer Ingelheim (I); Janssen (I); Pfizer (I) | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| Consulting or Advisory Role - Astellas Pharma; Bayer; Dendreon | 
| Research Funding - Ambry Genetics (Inst); Bavarian Nordic (Inst); Johnson & Johnson (Inst); Sotio (Inst) | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); EMD Serono (Inst); NantBioScience (Inst); Pfizer (Inst) | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| No Relationships to Disclose |